<?xml version="1.0" encoding="UTF-8"?>
<p>It has been estimated that most exacerbations of COPD are due to respiratory viral and/or bacterial infections. Thus, the major pharmacological components of managing exacerbations of COPD include SABAs, short-course systemic glucocorticoids, and antibiotics (
 <xref ref-type="bibr" rid="B108">Vestbo et al., 2013</xref>). However, anti-viral therapies are rarely prescribed, because specific anti-viral therapies do not exist, except for influenza virus and RSV. Treatment for influenza appears appropriate in patients with COPD (
 <xref ref-type="bibr" rid="B36">Harper et al., 2009</xref>), while the utility of treatment for RSV has not been confirmed in adults. It is doubtful that systemic corticosteroid treatment affects the clinical course of respiratory viral infections. 
 <xref ref-type="bibr" rid="B61">Lee et al. (2011)</xref> showed that short-course systemic steroid treatment did not affect viral load or shedding, and humoral immunity may be diminished by steroid treatment.
</p>
